Health care professionals must consider drug-related adverse events along with efficacy when they prescribe medications. In explaining such concepts as statistical significance and magnitude of effect, the author suggests how indirect comparisons of studies can be used to help guide treatment decisions, especially if patients are taking other agents and combination therapy.
You are here
P&T® Journal contents for December 2008
Presentations included voreloxin for acute myelogenous leukemia; azacytidine (Vidaza) and decitabine (Depo-Cyt) for myelodysplastic syndromes; lenalidomide (Revlimid) for lymphoma; and dasatinib (Sprycel), nilotinib (Tasigna), and other investigational agents for chronic myelogenous leukemia.
Fourth Annual Ophthalmic Drug Development and Delivery Summit; Third Annual Onmark National Payor/Provider Forum
Topics discussed at the ophthalmic meeting included medications for dry eye and for diabetes-related conditions. The Onmark Forum focused on the anticipated need for collaboration between oncologists and adjunctive personnel because of a workforce gap; online information gathering; and standardizing procedures.
Continuing Education Credit
Obesity can have deleterious effects on health, often leading to diabetes and cardiovascular disease. Bariatric surgery, diet and behavior modification, and current and investigational drug therapies are some of the tools that are available now to help the overweight patient population.